Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;6(3):e231723.
doi: 10.1001/jamanetworkopen.2023.1723.

Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital

Lauren G Santos  1   2 , Tatyana Buzdnitskaya  3 , Bradley A Rolf  1 , William Souza  3 , Mark Sienko  3 , Jose Alberto Ruiz-Bonilla  3 , Binay Shah  3 , Patrick Jewell  3 , Lindsay Jensen  3 , Martha Horike-Pyne  1 , Jo Ann Elrod  2 , Jennie Crews  1   2 , Mercy Laurino  2 , Kevin Austin Weeks  3 , Marianne E Dubard-Gault  1   2
Affiliations

Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital

Lauren G Santos et al. JAMA Netw Open. .

Abstract

Background: Patients with cancer seen in rural and underserved areas disproportionately face barriers to access genetic services. Genetic testing is critical to inform treatment decisions, for early detection of another cancer, and to identify at-risk family members who may benefit from screening and prevention.

Objective: To examine medical oncologists' genetic testing ordering trends for patients with cancer.

Design, setting, and participants: This prospective quality improvement study was performed in 2 phases over 6 months between August 1, 2020, and January 31, 2021, at a community network hospital. Phase 1 focused on observation of clinic processes. Phase 2 incorporated peer coaching from cancer genetics experts for medical oncologists at the community network hospital. The follow-up period lasted 9 months.

Main outcomes and measures: The number of genetic tests ordered was compared between phases.

Results: The study included 634 patients (mean [SD] age, 71.0 [10.8] years [range, 39-90 years]; 409 women [64.5%]; 585 White [92.3%]); 353 (55.7%) had breast cancer, 184 (29.0%) had prostate cancer, and 218 (34.4%) had a family history of cancer. Of the 634 patients with cancer, 29 of 415 (7.0%) received genetic testing in phase 1, and 25 of 219 (11.4%) received genetic testing in phase 2. Of the 29 patients who received testing in phase 1, 20 (69.0%) had germline genetic testing; 23 of 25 patients (92.0%) had germline genetic testing in phase 2. Uptake of germline genetic testing increased by 23.0% between phases, but the difference was not statistically significant (P = .06). Uptake of germline genetic testing was highest among patients with pancreatic cancer (4 of 19 [21.1%]) and ovarian cancer (6 of 35 [17.1%]); the National Comprehensive Cancer Network (NCCN) recommends offering genetic testing to all patients with pancreatic cancer and ovarian cancer.

Conclusions and relevance: This study suggests that peer coaching from cancer genetics experts was associated with an increase in ordering of genetic testing by medical oncologists. Efforts made to (1) standardize gathering of personal and family history of cancer, (2) review biomarker data suggestive of a hereditary cancer syndrome, (3) facilitate ordering tumor and/or germline genetic testing every time NCCN criteria are met, (4) encourage data sharing between institutions, and (5) advocate for universal coverage for genetic testing may help realize the benefits associated with precision oncology for patients and their families seeking care at community cancer centers.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Timeline of SARS-CoV-2 Infection Waves in the United States Using Data From the World Health Organization and the Centers for Disease Control and Prevention
See this image and copyright information in PMC

References

    1. Reilly M. Health disparities and access to healthcare in rural vs urban areas. Theory Action. 2021;14(2):6-27. doi: 10.3798/tia.1937-0237.2109 - DOI
    1. Stadler ZK, Maio A, Chakravarty D, et al. Therapeutic implications of germline testing in patients with advanced cancers. J Clin Oncol. 2021;39(24):2698-2709. doi: 10.1200/JCO.20.03661 - DOI - PMC - PubMed
    1. Hadar T, Mor P, Amit G, et al. Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer. JAMA Oncol. 2020;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059 - DOI - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. ; BRCA1 and BRCA2 Cohort Consortium . Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416. doi: 10.1001/jama.2017.7112 - DOI - PubMed
    1. Allen CG, Roberts M, Guan Y. Exploring predictors of genetic counseling and testing for hereditary breast and ovarian cancer: findings from the 2015 U.S. National Health Interview Survey. J Pers Med. 2019;9(2):26. doi: 10.3390/jpm9020026 - DOI - PMC - PubMed

Publication types